trial

A Repeat Dose Positron Emission Tomography Study With GSK1144814

NCTId NCT01209039
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 41 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2009-10-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
41 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2009-07-01
Primary completion
2009-10-25
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
GSK1144814

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

2 total
Harrow, United KingdomLondon, United Kingdom

Facts & assertions

4 sourced
Enrollment
41
Phase
PHASE1
Primary Completion Date
2009-10-25
Status
COMPLETED
relationships
The graph out of here
drug
GSK1144814
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication